Clinical trials: Active Rheumatoid Arthritis
Adult Onset Still's Disease
Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD
This study was designed to evaluate the efficacy and safety of canakinumab administered subcutaneously every 4 weeks for at least 48 weeks in Japanese patients with Adult-Onset Still's Disease (AOSD).
- Trial name
- NCT04717635
- Testing
- Canakinumab
- Where
- 9 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
The current study is designed to evaluate the safety and efficacy, including MRI imaging, across a range of VX-509 doses in subjects with active rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying…
- Trial name
- NCT01754935
- Testing
- VX-509
- Where
- 30 sites in United States, Denmark and 4 more
- Volunteers
- 43 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Rheumatoid Arthritis
ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate.
- Trial name
- NCT02387762
- Testing
- acalabrutinib
- Where
- 17 sites in United States
- Volunteers
- 31 people
- Sponsor
- Acerta Pharma BV
Rheumatoid Arthritis
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
This open-label study will evaluate the efficacy and safety of tocilizumab as monotherapy or in combination with methotrexate or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in participants with active…
- Trial name
- ACT-MOVE (NCT02046603)
- Testing
- Tocilizumab, DMARDs, Oral Corticosteroids
- Where
- 38 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis
The objective was to determine the effects of BIRB 796 BS on CRP and clinical parameters in Rheumatoid Arthritis as measures of efficacy, and on population pharmacokinetics and safety parameters
- Trial name
- NCT02209779
- Testing
- BIBR 796 BS
- Volunteers
- 167 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.
This 2 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo, both in combination with DMARDs, in patients with active rheumatoid arthritis who currently…
- Trial name
- NCT00773461
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 9 sites in China
- Volunteers
- 209 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate
The primary objective of this study is to determine the efficacy of oral SCIO-469 in patients with rheumatoid arthritis who are not receiving liver damaging (hepatotoxic) disease-modifying anti-rheumatic drugs (DMARDs).
- Trial name
- NCT00089921
- Testing
- SCIO-469
- Volunteers
- 302 people
- Sponsor
- Scios, Inc.
Rheumatoid Arthritis
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to severe active Rheumatoid Arthritis (RA) who…
- Trial name
- NCT03813199
- Testing
- ABX464 50mg, ABX464 100mg, Methotrexate
- Where
- 24 sites in Belgium, Czechia and 3 more
- Volunteers
- 60 people
- Sponsor
- Abivax S.A.
Rheumatoid Arthritis
A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis
This is a Phase III Study to Compare Efficacy and Safety of CT-P17 with Humira in Patients With Active Rheumatoid Arthritis
- Trial name
- NCT03789292
- Testing
- CT-P17 SC, Humira SC
- Where
- Bulgaria
- Volunteers
- 648 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study
This is a prospective, randomized, double-blind, parallel group, multicentre global phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of BOW015 (infliximab-EPIRUS) compared to Remicade in subjects with…
- Trial name
- NCT02683564
- Testing
- BOW015, Remicade
- Volunteers
- 548 people
- Sponsor
- Epirus Biopharmaceuticals (Switzerland) GmbH
Rheumatoid Arthritis, Psoriatic Arthritis
A Study of SPY072 in Rheumatic Disease
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
- Trial name
- SKYWAY-RD (NCT07148414)
- Testing
- SPY002-072
- Where
- 64 sites in United States, Bulgaria and 6 more
- Volunteers
- 285 people
- Sponsor
- Spyre Therapeutics, Inc.
Sjogren Syndrome
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
- Trial name
- NEPTUNUS-2 (NCT05349214)
- Testing
- VAY736
- Where
- 146 sites in United States, Argentina and 24 more
- Volunteers
- 506 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)
This study will assess the long-term safety and efficacy of repeat treatment courses of rituximab, in combination with methotrexate in a disease-modifying anti-rheumatic drug (DMARD) inadequate responder population of…
- Trial name
- NCT02093026
- Testing
- Rituximab, Methotrexate, Methylprednisolone
- Where
- 92 sites in United States, Australia and 14 more
- Volunteers
- 465 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis
This study includes two periods. In Period 1, Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice-daily oral LNK01001 Dose A or LNK01001 Dose B or a matching placebo for 12 weeks.
- Trial name
- NCT06099535
- Testing
- LNK01001 Dose A, LNK01001 Dose B
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
This 3 arm study will compare the safety and efficacy, with respect to a reduction in signs and symptoms and prevention of joint damage, of tocilizumab versus placebo, both in combination with methotrexate (MTX) in patients with…
- Trial name
- NCT00106535
- Testing
- tocilizumab [RoActemra/Actemra], Methotrexate
- Where
- 152 sites in United States, Australia and 14 more
- Volunteers
- 1,196 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
This study is designed to evaluate the safety and efficacy of VX-509, an oral JAK3 inhibitor, for treatment of subjects with active RA who have had an inadequate response to Methotrexate.
- Trial name
- NCT01590459
- Testing
- VX-509
- Where
- 94 sites in United States, Argentina and 12 more
- Volunteers
- 359 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Rheumatoid Arthritis
Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate
The study compared the efficacy and assessed the safety of secukinumab given as 3 intravenous (i.v.) loading doses or weekly sub-cutaneous (s.c.) loading doses, compared to placebo, followed by monthly s.c.
- Trial name
- NCT01359943
- Testing
- secukinumab (AIN457)
- Where
- 39 sites in United States, Bulgaria and 6 more
- Volunteers
- 221 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to assess the impact of JNJ-38518168 on rheumatoid arthritis (RA) disease-related biomarkers in synovial biopsy tissue and blood in participants with active RA despite methotrexate (MTX) therapy and…
- Trial name
- NCT01862224
- Testing
- JNJ-38518168, Methotrexate
- Where
- 2 sites in United States, Moldova
- Volunteers
- 21 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis.
- Trial name
- NCT00853385
- Testing
- CP 690,550, CP-690,550, Biologic TNFi
- Where
- 125 sites in United States, Australia and 19 more
- Volunteers
- 717 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)
A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.
- Trial name
- NCT00157872
- Testing
- MK0966; rofecoxib, Comparator: naproxen tablet 500 mg
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC